[Ocular tolerance of a new formulation of nonpreserved diclofenac]
Author(s): Chiambaretta F, Creuzot-Garcher C, Pilon F, Pouliquen P, Rebika H, Dubray C, Rigal D
Affiliation(s): Service d'Ophtalmologie, CHU de Clermont-Ferrand, Hopital Gabriel Montpied, Clermont-Ferrand, France.
Publication date & source: 2004-09, J Fr Ophtalmol., 27(7):739-44.
Publication type: Clinical Trial; Clinical Trial, Phase I; Randomized Controlled Trial
AIM: To compare the ocular tolerance of nonpreserved diclofenac versus thiomersal-preserved diclofenac in healthy volunteers. MATERIALS AND METHODS: Forty healthy volunteers instilled Dicloabak in the randomised eye and thiomersal-preserved diclofenac in the other eye, according to a strictly identical dosing regimen, for 28 days. Each volunteer thus served as his or her own control. The dose regimen was five drops/day for 7 days followed by three drops/day for 20 days. Ocular tolerance was assessed by the discomfort upon instillation (measured on a visual analogue scale [VAS]), subjective ocular symptoms following instillation (irritation/burning/stinging, eye dryness and foreign body sensation) and finally by an objective examination of the ocular surface. These criteria were evaluated on days 0, 14, 21 and 28. RESULTS: The subjective ocular symptoms following instillation were significantly lower in the nonpreserved group at Day 7 and nearly significantly lower until the end of the study. The biomicroscopy exam confirmed that there was better tolerance without thiomersal. There was less follicular-papillary conjunctivitis and a significantly better lissamine green score in the Dicloabak group. CONCLUSION: The results of this study demonstrate that the nonpreserved formulation of diclofenac is better tolerated by the ocular surface and thus constitutes a therapeutic benefit.
|